Have any significant insider buy/sell transactions been reported for SKYE in Q3/Q4 2025?

Based on a review of available Fintel data and SEC filings, no significant open market insider buy or sell transactions for Skye Bioscience, Inc. (SKYE) have been explicitly reported within the provided search results for Q3 (July 1 - September 30, 2025) or Q4 (October 1 - December 31, 2025) of 2025.

While Fintel's platform provides dedicated sections for "Latest Insider Trades," "CEO Purchases," and "Most Insider Buying/Selling", the specific transaction details for SKYE within the requested timeframe were not present in the search snippets. SEC filings for SKYE in 2025, such as the 2025 Proxy Statement, discuss equity awards like options and restricted stock units (RSUs) granted to executives and board members, and modifications to existing awards, primarily in late 2024 and early 2025. These are compensation-related grants rather than open market purchases or sales by insiders.

For the most up-to-date and granular information on insider trading activity for SKYE, it is recommended to directly consult the "Latest Insider Trades" section on the Fintel platform for Skye Bioscience, Inc..